CVRx (NASDAQ:CVRX) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

CVRx (NASDAQ:CVRX) posted its quarterly earnings results on Thursday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.01), FiscalAI reports. The company had revenue of $15.71 million for the quarter, compared to analysts’ expectations of $15.55 million. CVRx had a negative return on equity of 120.76% and a negative net margin of 89.14%.

Here are the key takeaways from CVRx’s conference call:

• 2026 revenue guidance was lowered to $58 million–$60 million, with third-quarter revenue expected at $13.5 million–$14.5 million, reflecting weaker anticipated second-half performance.
• Sales execution has been hampered by high turnover and slower-than-expected ramping of new territory managers, particularly in several regions with less-tenured leadership; CVRx does not expect to add sales territories for the rest of 2026.
• A major Medicare Advantage payer’s use of new prior-authorization tactics has pushed its 30-day approval rate below 30%, making physicians more hesitant to recommend Barostim for patients covered by that plan.
• Reimbursement trends outside that payer are improving, including a 60% overall Medicare Advantage 30-day approval rate, approval rates above 90% with Humana, approximately 96% payment across traditional Medicare contractors, and higher inpatient payment rates.
• CVRx reported second-quarter revenue of $15.7 million, up 16% year over year, and said the BENEFIT-HF trial is ahead of expectations for site activation and enrollment; however, the company also disclosed a Department of Justice civil investigative demand related to certain sales and marketing practices.

CVRx Trading Down 60.1%

Shares of CVRX traded down $3.57 during trading on Friday, reaching $2.37. 14,647,133 shares of the company traded hands, compared to its average volume of 417,343. The company has a quick ratio of 8.89, a current ratio of 10.20 and a debt-to-equity ratio of 2.01. The stock has a market cap of $62.90 million, a PE ratio of -1.17 and a beta of 0.81. The stock has a 50-day simple moving average of $5.26 and a 200-day simple moving average of $6.52. CVRx has a twelve month low of $2.30 and a twelve month high of $11.30.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CVRX. Craig Hallum lowered shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a report on Friday. Piper Sandler downgraded shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a report on Friday. Lake Street Capital lowered shares of CVRx from a “buy” rating to a “hold” rating and set a $3.50 price target on the stock. in a research report on Friday. Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 price objective on shares of CVRx in a report on Tuesday, April 14th. Finally, Wall Street Zen upgraded CVRx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $6.90.

Institutional Trading of CVRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CVRX. GSK plc purchased a new position in CVRx in the 4th quarter valued at approximately $7,154,000. Balyasny Asset Management L.P. increased its position in shares of CVRx by 65.5% during the second quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company’s stock worth $3,967,000 after acquiring an additional 267,063 shares during the period. Marshall Wace LLP increased its position in shares of CVRx by 238.1% during the second quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock worth $2,058,000 after acquiring an additional 246,548 shares during the period. Jane Street Group LLC raised its stake in shares of CVRx by 162.9% in the fourth quarter. Jane Street Group LLC now owns 225,349 shares of the company’s stock valued at $1,600,000 after acquiring an additional 139,643 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of CVRx by 102.6% in the third quarter. Bank of America Corp DE now owns 180,425 shares of the company’s stock valued at $1,456,000 after acquiring an additional 91,376 shares in the last quarter. Hedge funds and other institutional investors own 75.27% of the company’s stock.

Key Headlines Impacting CVRx

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: Second-quarter revenue was $15.71 million, slightly above the $15.55 million consensus estimate. The quarterly loss of $0.53 per share also improved from $0.57 per share a year earlier, although it narrowly missed the $0.52 consensus estimate. CVRx Reports Second Quarter 2026 Financial and Operating Results
• Neutral Sentiment: Lake Street Capital and Craig Hallum both lowered CVRx from “buy” to “hold.” Their new price targets of $3.50 and $4.00 remain above the recent trading level, indicating potential upside but reduced confidence in the company’s near-term execution. Analyst rating updates
• Negative Sentiment: CVRx cut third-quarter 2026 revenue guidance to $13.5 million–$14.5 million, well below the $16.9 million analyst consensus. Full-year 2026 revenue guidance was reduced to $58 million–$60 million from expectations of $65.4 million, signaling weaker growth and likely worsening operating leverage. CVRx forecasts 2026 revenue of $58M-$60M
• Negative Sentiment: The company identified sales-force productivity issues and Medicare Advantage reimbursement pressures as factors weighing on demand, raising concerns about the pace of adoption for its neuromodulation products. CVRx Q2 2026 earnings call transcript
• Negative Sentiment: Johnson Fistel announced an investigation into whether CVRx or its executives violated securities laws in connection with the revenue-guidance reduction and sales-execution disclosures. The investigation does not establish wrongdoing, but it adds legal and reputational risk. Johnson Fistel CVRx investigation

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.